Terms: = Prostate cancer AND CDH11, OB, 1009, ENSG00000140937, CAD11, P55287 AND Treatment
18 results:
1. The Role of Adipocytokines and their Receptors in prostate cancer: Adiponectin May Protect Against Progression.
Kashiwagi E; Kawahara T; Kinoshita F; Shiota M; Inokuchi J; Miyamoto H; Eto M
Anticancer Res; 2024 Apr; 44(4):1369-1376. PubMed ID: 38537999
[TBL] [Abstract] [Full Text] [Related]
2. Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer.
Lai C; Wu Z; Li Z; Huang X; Hu Z; Yu H; Yuan Z; Shi J; Hu J; Mulati Y; Liu C; Xu K
Clin Transl Oncol; 2024 May; 26(5):1240-1255. PubMed ID: 38070051
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of Viscum album L. Effect on Immune Escape Proteins PD-L1, PD-L2, and MHC-I in the prostate, Colon, Lung, and Breast cancer Cells.
Devi S; Gründemann C; Huber R; Kowarschik S
Complement Med Res; 2023; 30(5):386-392. PubMed ID: 36927644
[TBL] [Abstract] [Full Text] [Related]
4. Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer.
Kong D; Ye C; Zhang C; Sun X; Wang F; Chen R; Xiao G; He S; Xu J; Rao X; Ai J; Gao X; Li H; Su L
J Exp Clin Cancer Res; 2023 Feb; 42(1):45. PubMed ID: 36759880
[TBL] [Abstract] [Full Text] [Related]
5. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Buhigas C; Warren AY; Leung WK; Whitaker HC; Luxton HJ; Hawkins S; Kay J; Butler A; Xu Y; Woodcock DJ; Merson S; Frame FM; Sahli A; Abascal F; ; Martincorena I; Bova GS; Foster CS; Campbell P; Maitland NJ; Neal DE; Massie CE; Lynch AG; Eeles RA; Cooper CS; Wedge DC; Brewer DS
Mol Cancer; 2022 Sep; 21(1):183. PubMed ID: 36131292
[TBL] [Abstract] [Full Text] [Related]
6. Dietary tomato inhibits angiogenesis in TRAMP prostate cancer but is not protective with a Western-style diet in this pilot study.
Applegate CC; Lowerison MR; Hambley E; Song P; Wallig MA; Erdman JW
Sci Rep; 2021 Sep; 11(1):18548. PubMed ID: 34535690
[TBL] [Abstract] [Full Text] [Related]
7. Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa.
Mattila PO; Babar ZU; Suleman F
BMC Health Serv Res; 2021 Jul; 21(1):661. PubMed ID: 34229693
[TBL] [Abstract] [Full Text] [Related]
8. Leptin Promotes prostate cancer Proliferation and Migration by Stimulating STAT3 Pathway.
Gorrab A; Pagano A; Ayed K; Chebil M; Derouiche A; Kovacic H; Gati A
Nutr Cancer; 2021; 73(7):1217-1227. PubMed ID: 32698628
[TBL] [Abstract] [Full Text] [Related]
9. A Network Pharmacology Approach to Explore the Potential Mechanisms of Huangqin-Baishao Herb Pair in treatment of cancer.
Xu T; Wang Q; Liu M
Med Sci Monit; 2020 Jul; 26():e923199. PubMed ID: 32609659
[TBL] [Abstract] [Full Text] [Related]
10. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
[TBL] [Abstract] [Full Text] [Related]
11. Using individual patient anatomy to predict protocol compliance for prostate intensity-modulated radiotherapy.
Caine H; Whalley D; Kneebone A; McCloud P; Eade T
Med Dosim; 2016; 41(1):70-4. PubMed ID: 26755075
[TBL] [Abstract] [Full Text] [Related]
12. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract] [Full Text] [Related]
13. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.
Gasi Tandefelt D; Boormans JL; van der Korput HA; Jenster GW; Trapman J
Eur Urol; 2013 Dec; 64(6):941-50. PubMed ID: 23490727
[TBL] [Abstract] [Full Text] [Related]
14. Reliability of adverse symptom event reporting by clinicians.
Atkinson TM; Li Y; Coffey CW; Sit L; Shaw M; Lavene D; Bennett AV; Fruscione M; Rogak L; Hay J; Gönen M; Schrag D; Basch E
Qual Life Res; 2012 Sep; 21(7):1159-64. PubMed ID: 21984468
[TBL] [Abstract] [Full Text] [Related]
15. The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance.
van Poppel H; Haese A; Graefen M; de la Taille A; Irani J; de Reijke T; Remzi M; Marberger M
BJU Int; 2012 Feb; 109(3):360-6. PubMed ID: 21883822
[TBL] [Abstract] [Full Text] [Related]
16. [High-dose rate iridium-192 brachytherapy combined with external beam radiotherapy for localized prostate cancer].
Kasahara K; Inoue K; Karashima T; Inoue Y; Kariya S; Inomata T; Yoshida S; Shuin T
Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):572-8. PubMed ID: 11517568
[TBL] [Abstract] [Full Text] [Related]
17. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
[TBL] [Abstract] [Full Text] [Related]
18. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
Yamanaka H; Shida K
Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
[TBL] [Abstract] [Full Text] [Related]
